Recombinant promoter and vector for liver-specific expression and their application in the treatment of liver-related diseases
By designing a small-sized, highly specific, and high-expression-intensity recombinant liver-specific promoter, the problem of limited rAAV vector loading capacity has been solved, enabling efficient and specific gene expression in the liver, which is suitable for gene therapy of various liver-related diseases.
Patent Information
- Application Number
- CN202310683488.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-06-09
AI Technical Summary
In existing gene therapy technologies, the limited loading capacity of adeno-associated virus (rAAV) vectors leads to a reduction in promoter length, affecting the expression intensity and specificity of the target gene and making it difficult to achieve sustained high-intensity liver-specific gene expression.
A set of small-sized, highly specific, and high-expression-intensity recombinant liver-specific promoters, including HBVpS, HBVpL, HBVpM, hALBpL, hALBpS, FGBp, and SERPINA promoters, were designed to drive the expression of larger exogenous genes and bind to AAV vectors to achieve liver-specific gene therapy.
The increased loading capacity of the AAV vector ensures high-intensity and high-specificity gene expression in the liver, making it suitable for gene therapy of various liver-related diseases, especially the treatment of coagulation factor deficiency diseases such as hemophilia.
Smart Images

Figure CN116555266B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and in particular, the present invention relates to a recombinant promoter and vector for liver-specific expression and application thereof in the treatment of liver-related diseases. Background Art
[0002] The liver is an organ of the digestive system in animals that has metabolic functions. It is involved in multiple physiological processes such as metabolism, bile secretion, energy conversion, detoxification, coagulation, and immunity. Abnormal liver metabolism can lead to the occurrence of many diseases, such as hepatitis, liver fibrosis, cirrhosis, fatty liver, liver cancer, etc. In addition, diseases such as diabetes, obesity, and hemophilia are also related to abnormal liver metabolism. Liver metabolic diseases are mainly caused by overexpression or underexpression of certain genes. Liver-related diseases are an important factor that threatens human life and health, causing about 2 million deaths worldwide each year. Current medical methods and drugs are not effective in treating liver-related diseases. Not only are there risks of infectious diseases, but they can only temporarily alleviate the symptoms of liver-related diseases and cannot cure them.
[0003] Hemophilia B is a serious hereditary bleeding disease caused by a deficiency of coagulation factor IX (F9). It is an X-linked recessive trait with an incidence of 1 / 30,000 in males. F9 is synthesized by the liver and secreted into plasma. It exists in the form of zymogen under physiological conditions. When bleeding occurs, F9 is cut into an activated form by the upstream F11, and then cooperates with the activated F8 to cut the downstream F10, passing the coagulation factor cascade reaction downstream, and eventually leads to the step-by-step cutting of fibrinogen into fibrin monomers-soluble fibrin-cross-linked fibrin, thereby initiating a coagulation reaction. There is currently no specific drug to cure the coagulation dysfunction caused by the F9 gene defect. Generally, it can only be controlled by using related coagulation factors combined with local hemostatic treatment, but due to the short half-life of coagulation factors, frequent injection treatment is required.
[0004] In recent years, gene editing technology has been widely studied. With its increasing safety and efficacy, gene therapy has gradually been applied in clinical medicine. Gene therapy refers to editing defective genes at the DNA level, curing diseases by correcting gene defects or regulating gene expression. The blood supply and porous endothelial system of the liver provide a relatively easy way for cell or gene delivery, and the proliferation and regeneration ability of hepatocytes make gene therapy have unique advantages in the treatment of liver-related diseases. Gene therapy plays an important role in the treatment of many congenital or acquired liver-related diseases. For example, hereditary metabolic diseases, hepatitis, and cirrhosis may be controlled by gene therapy. Gene therapy can be achieved through a variety of vectors, including viral methods and non-viral methods, the latter including receptors, liposomes, lipid nanoparticles (Lipid Nanoparticle, LNP), etc. Adeno-associated virus (AAV) is a type of single-stranded linear DNA defective virus. Its genomic DNA is less than 5kb and has no envelope. So far, wild-type AAV has not been found to be pathogenic to humans. Artificially modified recombinant AAV (rAAV) has the advantages of good safety, low immunogenicity, broad tissue tropism, and non-integration into the host cell genome. It is currently a widely used gene therapy vector.
[0005] In order to enhance the efficacy of gene therapy, the current problem that needs to be overcome in this field is to ensure that the promoter can continuously and highly activate the precise expression of the target gene, thereby achieving precise positioning and high expression levels of the therapeutic gene, and reducing the toxic and side effects produced by expression in non-target tissues. In addition, due to the limitation of rAAV loading capacity, when loading larger genes, it is necessary to reduce the length of the promoter. Correspondingly, the key expression regulatory elements contained in the deletion sequence are also lost, and the expression intensity and specificity of the target gene will also decrease. Therefore, how to maintain the strength and specificity of the promoter to activate the target gene while minimizing the size of the promoter is another important issue that needs to be solved when using rAAV as a vector to deliver larger genes. Summary of the invention
[0006] In view of the above technical defects or improvement needs in the prior art, the object of the present invention is to provide a recombinant promoter and vector for liver-specific expression and their application in the treatment of liver-related diseases.
[0007] The present invention screened out a group of recombinant liver-specific promoters with small size, high specificity and high expression intensity through a large number of experiments. The recombinant liver-specific promoter can be used to drive the expression of larger exogenous genes, thereby solving the technical problem of limited loading capacity of rAAV vectors used in existing gene therapy technologies. In addition, the promoter has high specificity, expression intensity and safety, and is suitable for rAAV-mediated gene therapy.
[0008] In order to achieve the above object, the present invention adopts the following technical solutions:
[0009] The first aspect of the present invention provides a set of recombinant liver-specific promoters.
[0010] Further, the recombinant liver-specific promoter includes HBVpS promoter, HBVpL promoter, HBVpM promoter, hALBpL promoter, hALBpS promoter, FGBp promoter, SERPINA promoter;
[0011] Preferably, the nucleotide sequence of the HBVpS promoter is as shown in SEQ ID NO: 6 or a nucleotide sequence having at least 90% identity with SEQ ID NO: 6;
[0012] Preferably, the nucleotide sequence of the HBVpL promoter is as shown in SEQ ID NO:4 or a nucleotide sequence having at least 90% identity with SEQ ID NO:4;
[0013] Preferably, the nucleotide sequence of the HBVpM promoter is as shown in SEQ ID NO:5 or a nucleotide sequence having at least 90% identity with SEQ ID NO:5;
[0014] Preferably, the nucleotide sequence of the hALBpL promoter is as shown in SEQ ID NO: 2 or a nucleotide sequence having at least 90% identity with SEQ ID NO: 2;
[0015] Preferably, the nucleotide sequence of the hALBpS promoter is as shown in SEQ ID NO: 1 or a nucleotide sequence having at least 90% identity with SEQ ID NO: 1;
[0016] Preferably, the nucleotide sequence of the FGBp promoter is as shown in SEQ ID NO: 3 or a nucleotide sequence having at least 90% identity with SEQ ID NO: 3;
[0017] Preferably, the nucleotide sequence of the SERPINA promoter is as shown in SEQ ID NO:7 or a nucleotide sequence having at least 90% identity with SEQ ID NO:7.
[0018] In some embodiments, the HBVpS promoter, HBVpL promoter, HBVpM promoter, hALBpL promoter, hALBpS promoter, FGBp promoter, and SERPINA promoter described in the present invention are not limited to the above-mentioned nucleotide sequences. The recombinant promoter corresponding to the nucleotide sequence that has at least 90% identity with the above-mentioned nucleotide sequence, that is, the nucleotide sequence obtained by replacing the nucleotides at any one or more positions with any other nucleotides on the basis of the corresponding nucleotide sequence, is within the protection scope of the present invention as long as the nucleotide sequence has at least 90% identity with the above-mentioned nucleotide sequence of the present invention.
[0019] A second aspect of the present invention provides a set of recombinant nucleic acid molecules.
[0020] Further, the recombinant nucleic acid molecule comprises the recombinant liver-specific promoter described in the first aspect of the present invention;
[0021] Preferably, the nucleotide sequence of the recombinant nucleic acid molecule is as shown in any one of SEQ ID NO:6, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:2, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, or a nucleotide sequence that is at least 90% identical to any one of SEQ ID NO:6, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:2, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7.
[0022] A third aspect of the invention provides a set of expression cassettes.
[0023] Further, the expression cassette comprises the recombinant nucleic acid molecule described in the second aspect of the present invention and a nucleotide sequence encoding a target gene;
[0024] Preferably, the recombinant nucleic acid molecule described in the second aspect of the present invention is operably linked to the upstream of the target gene;
[0025] More preferably, the recombinant nucleic acid molecule can promote the specific expression of the target gene in liver tissue;
[0026] Most preferably, the target gene comprises F9, F9 / 384L, F8, F11, GH, PTH, GRF, FSH, LH, hCG, VEGF, angiopoietin, angiostatin, GCSF, EPO, CTGF, bFGF, aFGF, EGF, PDGF, IGF-I, GAA, IGF-II, and / or fluorescent protein gene;
[0027] Most preferably, the fluorescent protein comprises EGFP, mCherry, GFP, YFP, EYFP, BFP, EBFP, CFP, ECFP, RFP, hfGFP, hfYFP, OFP, dsRed, qFP611, Dronpa, TagRFP, KFP, EosFP, IrisFP, Dendra, Kaede, and / or KikGr1.
[0028] The fourth aspect of the present invention provides a group of recombinant expression vectors.
[0029] Further, the recombinant expression vector comprises the recombinant nucleic acid molecule described in the second aspect of the present invention, and / or the expression cassette described in the third aspect of the present invention;
[0030] Preferably, the expression vector comprises a viral vector or a plasmid vector;
[0031] More preferably, the viral vector includes an adeno-associated viral vector, an adenoviral vector, a lentiviral vector, a retroviral vector, an alphaviral vector, a herpes virus vector, an Epstein-Barr virus vector, or a vaccinia virus vector;
[0032] Most preferably, the adeno-associated virus vector includes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 8, and AAV2 / 9.
[0033] In some embodiments, the recombinant expression vector may further comprise one or more of the following elements: an origin of replication, a selectable marker, and a multiple cloning site.
[0034] In some embodiments, the recombinant liver-specific promoter provided by the first aspect of the present invention is inserted into an AAV gene therapy vector. The AAV gene therapy vector can encode multiple components (e.g., capsid protein, ITR, etc.), which can be the same or different serotypes, and the vector can encode one or more therapeutic genes or genes of interest (target genes).
[0035] In some embodiments, the target gene of the present invention includes, but is not limited to: one or more therapeutic genes, therapeutic proteins, therapeutic RNA (e.g., siRNA, miRNA or shRNA targeting a mutated or overexpressed gene), a gene of interest (e.g., a gene that is underexpressed or mutated in a subject), and / or a protein of interest (e.g., a protein that is underexpressed or mutated in a subject). The target gene of the present invention may include a nucleotide sequence encoding a therapeutic protein, therapeutic RNA or a fragment thereof.
[0036] In some embodiments, the therapeutic protein can be a primate protein, a non-primate protein, or a human protein, including but not limited to: coagulation factor IX (F9), coagulation factor VIII (F8), F9 mutant (F9 / 384L), insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiogenin, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factor I and II (IGF-I and IGF-II), transforming growth factor of Any one of the growth factor alpha superfamily (including TGFα, activin, inhibin) or any one of the bone morphogenetic proteins (BMP) BMP1-15, any one of the heregluin / neuromodulin / ARIA / nerve sheath differentiation factor (NDF) family of growth factors, brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), facial neurons, agrin, any one of the semaphorin / brain degeneration protein family, neurite outgrowth guidance factor-1 and neurite outgrowth guidance factor-2, hepatocyte growth factor (HGF), ephrin, noggin, phonin, tyrosine hydroxylase, acid alpha-glucosidase (acidalpha-glucosidase, GAA) and modified forms thereof, including variants, derivatives or equivalents.
[0037] In some embodiments, the serotype of the AAV gene therapy vector is not particularly limited and may include, but is not limited to, AAV serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11. In some embodiments, AAV is chimeric, meaning that it contains components from at least two AAV serotypes, such as ITRs of AAV2 and capsid proteins of AAV8. In some embodiments, gene therapy may include administering multiple AAV gene therapy vectors, and the vectors may be of the same or different serotypes.
[0038] In some embodiments, the AAV capsid is not a wild-type capsid but a recombinant AAV (rAAV), such as rAAV2 / 8, which comprises at least a portion of AAV2 and AAV8. For example, the VP1 capsid protein may be composed of a hybrid amino acid sequence between AAV2 and AAV8, while the VP2 and VP3 capsids may be derived from the AAV8 serotype.
[0039] A fifth aspect of the present invention provides a mammalian host cell.
[0040] Further, the mammalian host cell comprises the expression cassette described in the third aspect of the present invention, and / or the recombinant expression vector described in the fourth aspect of the present invention;
[0041] Preferably, the mammalian host cell is obtained by introducing the expression cassette described in the third aspect of the present invention and / or the recombinant expression vector described in the fourth aspect of the present invention into a host cell;
[0042] More preferably, the introduction method comprises lipofection, microinjection, electroporation, plasmid vector, retroviral vector, lentiviral vector, poxvirus vector, herpes simplex virus vector, adenovirus vector, adeno-associated virus vector;
[0043] More preferably, the host cell comprises a mouse cell, a rat cell, a hamster cell, a monkey cell, and / or a human cell.
[0044] In some embodiments, the host cell is a mammalian cell, and preferred mammalian cells include mouse cells, rat cells, hamster cells, monkey cells and human cells. Examples of such cells include HEK cells and derivatives (e.g., HEK293, HEK293T, HEK293A), PerC6 cells, 911 cells, CHO cells, HCT116 cells, HeLa cells, COS cells and VERO cells; cancer cells such as HepG2, A549 and MCF7; primary cells isolated from human or animal biopsies; and stem cells (including pluripotent cells, such as embryonic stem cells and induced pluripotent stem (iPS) cells; and pluripotent stem cells, such as hematopoietic stem cells, mesenchymal stem cells, etc.).
[0045] The present invention also provides a mammal, the genome of which comprises the recombinant nucleic acid molecule, expression cassette, and / or recombinant expression vector as described above, the recombinant nucleic acid molecule, expression cassette, and / or recombinant expression vector being inserted into the genome of the mammal so that the recombinant nucleic acid molecule of the present invention is operably linked to a target gene, so that the target gene is expressed in one or more cells of the mammal. Preferably, the mammal is a non-human mammal, more preferably, the mammal is a mouse or a rat.
[0046] A sixth aspect of the present invention provides a pharmaceutical composition for treating liver-related diseases.
[0047] Further, the pharmaceutical composition comprises the expression cassette described in the third aspect of the present invention, the recombinant expression vector described in the fourth aspect of the present invention, and / or the mammalian host cell described in the fifth aspect of the present invention;
[0048] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient;
[0049] Preferably, the target gene includes F9, F9 / 384L, F8, F11, GH, PTH, GRF, FSH, LH, hCG, VEGF, angiopoietin, angiostatin, GCSF, EPO, CTGF, bFGF, aFGF, EGF, PDGF, IGF-I, GAA, and / or IGF-II gene;
[0050] Preferably, the liver-related diseases include hemophilia, hepatitis, liver fibrosis, cirrhosis, alcoholic liver disease, fatty liver disease, liver cancer, diabetes, obesity, hyperlipidemia, hereditary cholestasis, Wilson's disease, hereditary hemochromatosis, type 1 tyrosinemia, α-1 antitrypsin deficiency, argininosuccinic aciduria, liver cancer, and / or Pompe's disease;
[0051] More preferably, the hemophilia includes hemophilia A, hemophilia B, and / or hemophilia C;
[0052] Most preferably, the hemophilia is hemophilia B.
[0053] In some embodiments, the pharmaceutical composition may further comprise an immunosuppressant, including but not limited to cyclosporine, tacrolimus, rapamycin, cyclophosphamide, methotrexate, azathioprine, mercaptopurine, fluoropyrimidine, mycophenolic acid, dactinomycin, fingolimod, T cell receptor antibody or binding protein, muromonab-CD3, IL-2 receptor antibody or binding protein, basiliximab, daclizumab, recombinant IFN-β, TNF-α antibody or binding protein, infliximab, etanercept, and / or adalimumab.
[0054] In some embodiments, the pharmaceutically acceptable carrier and / or excipient refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient (the expression cassette described in the third aspect of the invention, the recombinant expression vector described in the fourth aspect of the invention, and / or the mammalian host cell described in the fifth aspect of the invention), which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes but is not limited to: preservatives, chemical stabilizers, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, preservatives include but are not limited to: chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, paraben, vanillin, glycerol, carbolic acid, and parachlorophenol; chemical stabilizers include but are not limited to: gelatin, albumin, citric acid, malic acid, and calcium bicarbonate; pH adjusters include but are not limited to: phosphate buffer, citrate buffer, and borate buffer; surfactants include but are not limited to: cationic, anionic, and non-ionic surfactants, such as Tween-80; ionic strength enhancers include but are not limited to: sodium chloride, potassium chloride, and calcium chloride.
[0055] In some embodiments, the administration route of the pharmaceutical composition of the present invention includes conventional and pharmaceutically acceptable administration routes, including but not limited to: direct delivery to a desired organ (e.g., liver (optionally via the hepatic artery) or lung), oral, inhaled, intranasal, intratracheal, intraarterial, intraocular, intravenous, intramuscular, subcutaneous, intradermal and other administration routes. If desired, the administration routes can be combined.
[0056] A seventh aspect of the present invention provides a liver-specific tracer.
[0057] Further, the liver tracer comprises the expression cassette described in the third aspect of the present invention, and / or the recombinant expression vector described in the fourth aspect of the present invention;
[0058] Preferably, the target gene includes a fluorescent protein gene;
[0059] More preferably, the fluorescent protein includes EGFP, mCherry, GFP, YFP, EYFP, BFP, EBFP, CFP, ECFP, RFP, hfGFP, hfYFP, OFP, dsRed, qFP611, Dronpa, TagRFP, KFP, EosFP, IrisFP, Dendra, Kaede, and / or KikGr1.
[0060] In some embodiments, the fluorescent protein includes but is not limited to: green fluorescent protein (GFP), GFP-like fluorescent protein, enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), enhanced blue fluorescent protein (EBFP), cyan fluorescent protein (CFP), enhanced cyan fluorescent protein (ECFP); red fluorescent protein, superfolded GFP, superfolded YFP, orange fluorescent protein, red fluorescent protein, small super red fluorescent protein, FMA-binding fluorescent protein, dsRed, qFP611, Dronpa, TagRFP, KFP, EosFP, IrisFP, Dendra, Kaede, KikGr1, emerald fluorescent protein, Azami Green, mWasabi, TagGFP, TurboGFP, AcGFP, ZsGreen, T-Sapphire and fragments or derivatives thereof.
[0061] An eighth aspect of the present invention provides a method for expressing a target gene in the liver.
[0062] Furthermore, the method comprises the following steps: inserting the target gene into the downstream of the recombinant liver-specific promoter in the recombinant expression vector described in the fourth aspect of the present invention, and promoting the expression of the target gene in liver tissue by the recombinant liver-specific promoter;
[0063] Preferably, the target gene includes F9, F9 / 384L, F8, F11, GH, PTH, GRF, FSH, LH, hCG, VEGF, angiopoietin, angiostatin, GCSF, EPO, CTGF, bFGF, aFGF, EGF, PDGF, IGF-I, GAA, and / or IGF-II genes.
[0064] A ninth aspect of the present invention provides the application of any of the following aspects:
[0065] (1) Use of the recombinant liver-specific promoter described in the first aspect of the present invention, the recombinant nucleic acid molecule described in the second aspect of the present invention, the expression cassette described in the third aspect of the present invention, and / or the recombinant expression vector described in the fourth aspect of the present invention in promoting the specific expression of a target gene or nucleic acid fragment in the liver;
[0066] (2) Application of the liver-specific tracer described in the sixth aspect of the present invention in dynamic imaging to accurately evaluate liver function;
[0067] (3) Use of the recombinant liver-specific promoter described in the first aspect of the present invention, the recombinant nucleic acid molecule described in the second aspect of the present invention, the expression cassette described in the third aspect of the present invention, the recombinant expression vector described in the fourth aspect of the present invention, the mammalian host cell described in the fifth aspect of the present invention, and / or the pharmaceutical composition described in the sixth aspect of the present invention in the preparation of a drug for treating liver-related diseases.
[0068] Further, the liver-related diseases include hemophilia, hepatitis, liver fibrosis, cirrhosis, alcoholic liver disease, fatty liver disease, liver cancer, diabetes, obesity, hyperlipidemia, hereditary cholestasis, Wilson's disease, hereditary hemochromatosis, type 1 tyrosinemia, α-1 antitrypsin deficiency, argininosuccinic aciduria, liver cancer, and / or Pompe's disease;
[0069] Preferably, the hemophilia comprises hemophilia A, hemophilia B, and / or hemophilia C;
[0070] More preferably, the hemophilia is hemophilia B.
[0071] The present invention also provides a method for treating liver-related diseases in a subject in need thereof, the method comprising: administering to a subject in need thereof a therapeutically effective amount of the recombinant nucleic acid molecule described in the second aspect of the present invention, the expression cassette described in the third aspect of the present invention, the recombinant expression vector described in the fourth aspect of the present invention, the mammalian host cell described in the fifth aspect of the present invention, and / or the pharmaceutical composition described in the sixth aspect of the present invention.
[0072] In some embodiments, the recombinant expression vector can use different delivery vectors, including viral and non-viral vectors, wherein viral vectors include adeno-associated viral vectors, γ-retroviral vectors, lentiviral vectors, adenoviral vectors, etc.; non-viral vectors include receptors, liposomes, LNPs, etc. In the animal level experiment of the present invention, an adeno-associated viral vector is used. At the same time, in order to specifically deliver therapeutic genes to liver tissue and / or liver cells, rAAV2-8 with liver specificity and high delivery efficiency is selected as a vector, and rAAV2 is used as a control vector. The vector genome described herein comprises a nucleic acid molecule of any one of the recombinant liver-specific promoters provided herein, and the nucleic acid molecule is connected to a nucleotide encoding a target gene. In a specific embodiment of the present invention, the nucleic acid molecule is connected to a nucleic acid molecule encoding F9 and variant F9 / 384L.
[0073] The in vitro experimental cells used in the present invention are human liver cancer cells HepG2, and liver-derived cells of other species including humans, such as Huh7, Hep1-6 and other cells, can also be used. The in vivo experimental animals used in the present invention are mice, and experimental animals such as rats, rabbits, and monkeys can also be used. The administration method used in the present invention is AAV delivery and tail vein injection, and the selected vector can also be delivered to the subject by any suitable method including intravenous injection, ex vivo transduction, transfection, electroporation, liposome delivery, membrane fusion technology, high-speed DNA-coated micropellets, viral infection or protoplast fusion to introduce the target gene into the subject. The recombinant virus particles, capsids or vectors disclosed in the present invention can be delivered to the liver through the hepatic artery, portal vein or intravenously to obtain therapeutic levels of therapeutic proteins or coagulation factors in the blood.
[0074] In some embodiments, the liver-related diseases described in the present invention include diseases or conditions related to the liver, including but not limited to: hemophilia (hemophilia A, hemophilia B), hepatitis, liver fibrosis, cirrhosis, alcoholic liver disease, fatty liver, liver cancer, diabetes, obesity, hyperlipidemia, hereditary cholestasis, Wilson's disease, hereditary hemochromatosis, type 1 tyrosinemia, alpha-1 antitrypsin deficiency, argininosuccinic aciduria, liver cancer, Pompe disease (glycogen storage disease type II), hepatic glycogen storage disease, urea cycle disorder , Crigler-Najjar syndrome, familial amyloid polyneuropathy, atypical hemolytic uremic syndrome-1, primary urinary oxalate excess type 1, maple syrup urine disease, acute intermittent porphyria, coagulopathy / dyscoagulopathy, GSD1A, homozygous familial hypercholesterolemia, organic aciduria, cystic fibrosis, erythropoietic protoporphyria, Gaucher disease, familial hypercholesterolemia, ornithine transcarbamylase deficiency (OTC), phenylketonuria (PKU), acute intermittent porphyria (A IP), age-related macular degeneration, amyotrophic lateral sclerosis (ALS), cystic fibrosis, paralysis, Alzheimer's disease, Parkinson's disease, Huntington's disease (HD), arthritis, Batten disease, Canavan disease, citrullinemia type 1, rheumatoid arthritis, epilepsy, congestive heart failure, cystic fibrosis, Duchene muscular dystrophy, dyslipidemia, glycogen storage disease type I (GSD-I), hereditary emphysema, homozygous familial hyperglycemia (HoFH), Leber congenital amaurosis, a malonic acidemia, spinal muscular atrophy, paralysis, epilepsy, Pompe disease, Tay-Sachs disease, hyperoxaluria (PH-1), spinocerebellar ataxia type 1 (SCA-1), SCA-3, u-dystrophin, Gaucher disease type II or III, arrhythmogenic right ventricular cardiomyopathy (ARVC), Fabry disease, familial Mediterranean fever (FMF), propionic acidemia, fragile X syndrome, Rett syndrome, Niemann-Pick disease, Krabbe disease.
[0075] In some embodiments, the AAV gene therapy vectors provided by the present invention can be used to treat coagulation disorders, lysosomal storage disorders, and metabolic disorders.
[0076] Further, the coagulation disorder may include coagulation factors VII, VIII, IX and X, XI, V, XII, II, Willebrand factor deficiency, FV / FVIII combined deficiency, thalassemia, etc.
[0077] Further, the lysosomal storage disorder may be due to a lack of specific enzymes that break down certain lipids (fats) or carbohydrates (sugars) in body cells. Since the body cannot break down the fats or carbohydrates targeted by the enzymes for recycling, these may accumulate in the lysosomes of the cells, disrupting normal function and causing lysosomal storage disorders. Lysosomal disorders may include Fabry disease, Krabbe disease (childhood or late onset), galactosialidase storage disease, Fabry disease (α-galactosidase A), Schindler disease (α-galactosidase B), β-galactosidase / GM1 ganglioside, GM2 ganglioside, Gaucher disease type I, II and III, sphingomyelinase, lysosomal acid lipase deficiency, Nieto-Pitt disease A and B, sulfatide storage disease, saponin B deficiency, multiple sulfatase deficiency, mucopolysaccharidosis, hyaluronidase deficiency, glycogen storage disease, cholesterol ester storage disease, etc.
[0078] Further, the metabolic disorder may include ornithine transcarbamylase deficiency, phenylketonuria, propionic acidemia, methylmalonic acidemia, primary hyperoxaluria, and the like.
[0079] In some embodiments, the subject of the present invention includes humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates (e.g., cynomolgus monkeys), sheep, dogs, cattle, chickens, amphibians and reptiles. In a specific embodiment of the present invention, the subject is preferably a human.
[0080] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0081] The present invention provides a group of novel recombinant liver-specific promoters, which can be used to drive the expression of larger exogenous genes, thereby solving the technical problem of limited loading capacity of rAAV vectors used in existing gene therapy technologies. In addition, the promoters have high specificity, expression intensity and safety, and are suitable for rAAV-mediated gene therapy, providing good clues for the development of gene drugs related to various diseases such as liver metabolic diseases, hemophilia caused by coagulation factor deficiency, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The rAAV expression vector map containing the FGBp promoter constructed by the present invention;
[0083] Figure 2 A map of the rAAV expression vector containing the hALBpS promoter constructed in the present invention;
[0084] Figure 3 A map of the rAAV expression vector containing the hALBpL promoter constructed in the present invention;
[0085] Figure 4 The map of the rAAV expression vector containing the SERPINA promoter constructed in the present invention;
[0086] Figure 5 A map of the rAAV expression vector containing the HBVpL promoter constructed in the present invention;
[0087] Figure 6 A map of the rAAV expression vector containing the HBVpM promoter constructed in the present invention;
[0088] Figure 7 A map of the rAAV expression vector containing the HBVpS promoter constructed in the present invention;
[0089] Figure 8 The graphs are the comparison results of liver-specific expression activities of different promoters, wherein, Figure A: SFFV promoter, Figure B: HBVpS promoter, Figure C: HBVpM promoter, Figure D: HBVpL promoter, Figure E: hALBpL promoter, Figure F: hALBpS promoter, Figure G: FGBp promoter, Figure H: SERPINA promoter;
[0090] Fig. 9The comparison results of qPCR validation of the specific activation of different liver-specific promoters in hepatocyte HepG2, including: Figure A: comparison results of 7 different promoters, Figure B: comparison results of HBVpS, HBVpL and HBVpM promoters, Figure C: comparison results of hALBpS, hALBpL, FGBp and SERPINA promoters;
[0091] Fig.10 These are comparative results of qPCR detection of F9 expression levels of different liver-specific promoters in vivo, among which, Figure A: F9 mRNA content in mouse liver, kidney, heart, and brain tissues on the 7th day after injection, Figure B: F9 mRNA content in mouse liver, kidney, heart, and brain tissues on the 21st day after injection, Figure C: F9 mRNA content in mouse liver, kidney, heart, brain, testis, quadriceps, large intestine, small intestine, stomach, and lung tissues on the 21st day after injection. DETAILED DESCRIPTION
[0092] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. In order to facilitate understanding of the present invention, the following terms involved in the present invention are explained here:
[0093] As used herein, the term "and / or" is meant to encompass any and all possible combinations of one or more of the listed items, as well as no combinations when interpreted as the alternative "or".
[0094] As used herein, the terms “comprise” or “comprising” mean including stated elements or components but not excluding other elements or components.
[0095] As used herein, the term "F9" refers to the coagulation factor IX gene, also known as FIX, which is a serine protease belonging to the peptidase family S1, and hemophilia B is caused by a lack of F9. In addition, the term "F8" refers to the coagulation factor VIII gene, also known as FVIII, and hemophilia A is caused by a lack of F8. The term "F11" refers to the coagulation factor XI gene, also known as FXI, and hemophilia C is caused by a lack of F11.
[0096] As used herein, the term "F9 / 384L" refers to a mutant coagulation factor IX (F9) protein in which position 384 is changed from arginine to leucine (R384L, also known as fixpadua), which results in a 5-10-fold increase in the coagulation activity of coagulation factor IX.
[0097] As used herein, the term "administering" includes any route of introducing or delivering a substance (e.g., a recombinant nucleic acid molecule, an expression cassette, a recombinant expression vector, a mammalian host cell, a pharmaceutical composition, etc. provided by the present invention) to a subject to perform its intended function. Administration can be carried out by any suitable route, including oral, intranasal, intraocular, ophthalmic, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous) or topical. Administration includes self-administration and administration by others.
[0098] As used herein, the term "therapeutically effective amount" refers to a dose or plasma concentration that provides a specific pharmacological effect in a subject for which the disclosed AAV gene therapy vectors are administered, for example, to express a therapeutic gene or gene of interest in a target cell / organ. It should be emphasized that a therapeutically effective amount or therapeutic level of an AAV vector is not always effective in treating the conditions described herein, even if such a dose is considered a therapeutically effective amount by a person skilled in the art. These amounts can be adjusted by a person skilled in the art according to standard practice required for the treatment of a particular subject and / or condition. The therapeutically effective amount may vary depending on the route of administration and dosage form, the age and weight of the subject, and / or the disease or condition being treated.
[0099] It should be understood that the therapeutic response to a disease or condition can be repeatedly administered. Therefore, the therapeutically effective amount comprises a divided dose, which promotes the achievement of a therapeutic effect in a subject together with the previous or subsequent administration combination. For example, during the course of treatment, the material of the therapeutically effective amount can be administered in a single dose or in multiple doses, such as every day. However, the therapeutically effective amount depends on the subject being treated, the severity and type of the condition being treated, and the mode of administration. The material in a unit dosage form can be packaged in a therapeutic amount or multiple therapeutic amounts, such as in a vial (e.g., with a pierceable cover) or a syringe with a sterile component.
[0100] As used herein, the term "identity" refers to the sequence similarity between two nucleic acid molecules or between two peptides. Identity can be determined by comparing positions in each sequence, which can be aligned for the purpose of comparison. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences.
[0101] As used herein, the term "expression cassette" refers to a nucleic acid comprising a nucleotide sequence (e.g., a coding sequence and a sequence necessary for expressing the coding sequence). The term expression cassette includes regions of a genome, including regions that have been edited by genome editing techniques. Those skilled in the art will recognize that the inserted polynucleotide sequence need not be identical, but may only be substantially similar to the gene sequence from which it is derived.
[0102] As used herein, the term "gene therapy" refers to the introduction of a heterologous nucleic acid molecule into one or more recipient cells, wherein the expression of the heterologous nucleic acid molecule in the recipient cells affects the function of the cells and affects the therapeutic effect in the subject. For example, the heterologous nucleic acid molecule can encode a protein, which affects the function of the recipient cells.
[0103] As used herein, the term "operably linked" means that a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, the DNA sequences that are operably linked are continuous and, if necessary, connect two protein coding regions in the same reading frame.
[0104] In order to promote the expression of the target protein in liver tissue and / or liver cells, the present invention designs liver-specific promoters with different sequences and lengths. The liver-specific promoter can be operably combined with a heterologous nucleic acid sequence encoding the target protein and included in a viral vector (such as an adeno-associated viral vector), and can promote significantly increased protein expression in the liver and / or liver cells compared to other tissues and / or cell types.
[0105] The coagulation factor IX (F9) gene and the F9 mutant F9 / 384L are nucleic acid molecules for gene therapy of hemophilia B. The liver-specific promoter is operably linked to the nucleic acid sequence encoding the F9 and F9 / 384L proteins and packaged through a viral vector (rAAV) for targeted delivery to liver tissue and / or hepatocytes. To treat other liver-related diseases, different therapeutic gene nucleic acid sequences can be combined with promoters to achieve liver-specific expression of different genes, thereby playing a role in disease treatment.
[0106] The present invention has verified through comparative experiments that the hALBpL promoter in the recombinant promoter described in the present invention is significantly better than the unaltered wild-type Albumin gene promoter in driving the expression of the target gene in the liver, and the HBVpS promoter, HBVpM promoter, and HBVpL promoter in the recombinant promoter described in the present invention are significantly better than the unaltered wild-type HBV core antigen promoter in driving the expression of the target gene in the liver. This result is a technical effect that was unexpected by those skilled in the art.
[0107] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and are not to be construed as limiting the present invention. It will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purposes of the present invention, and that the scope of the present invention is defined by the claims and their equivalents. The experimental methods for which specific conditions are not specified in the following examples are usually tested under conventional conditions or under conditions recommended by the manufacturer.
[0108] The experimental material information used in each embodiment of the present invention is shown in Table 1 below.
[0109] Table 1 Experimental materials
[0110]
[0111] Example 1 Recombinant promoter fragment sequence
[0112] The present invention designs recombinant promoters of different lengths, which include a first response element, a TATA box and a transcription start site (TSS). Different recombinant promoters can change the length and modification of sequence fragments according to needs to better improve the specific expression ability of the target gene in the liver.
[0113] The recombinant promoters designed by the present invention include hALBpS promoter, hALBpL promoter, FGBp promoter, HBVpL promoter, HBVpM promoter, HBVpS promoter, and SERPINA promoter, and their corresponding sequence information is shown in Table 2 below.
[0114] Table 2 Sequence information of recombinant promoter
[0115]
[0116]
[0117] Example 2 Construction of rAAV expression vectors containing different promoters
[0118] The expression vector used in this example is synthesized by Universal Biotechnology with AAV2 expression vector as the backbone, and the different promoters and reporter gene eGFP sequences designed in Example 1 are respectively inserted to construct the rAAV expression vector map containing FGBp promoter, the rAAV expression vector map containing hALBpS promoter, the rAAV expression vector map containing hALBpL promoter, the rAAV expression vector map containing SERPINA promoter, the rAAV expression vector map containing HBVpL promoter, the rAAV expression vector map containing HBVpM promoter, and the rAAV expression vector map containing HBVpS promoter. Figure 1-Figure 7 .
[0119] Example 3 Comparison of the effects of different promoters on the EGFP fluorescent gene under fluorescence microscope
[0120] 1. Experimental methods
[0121] In this example, an adeno-associated virus was packaged with an eGFP reporter gene expression plasmid carrying a constitutive promoter SFFV or different liver-specific promoters designed in Example 1 of the present invention, and the hepatocyte cell line HepG2 and different control cell lines HEK293T (human embryonic kidney cell line), HeLa (cervical cancer cell line), and NSC34 (neuronal cell line) were infected, and the eGFP fluorescence intensity of different promoter groups was observed 48 hours after infection. SFFV-eGFP expression was used as an internal reference for eGFP expression in different cell lines, and the promoter that specifically promoted eGFP expression in the hepatocyte cell line was screened by the ability of different liver-specific promoters to promote the expression of the reporter gene eGFP in several cell lines.
[0122] (1) Adeno-associated virus packaging
[0123] ①Put HEK293T cells into the corresponding culture dish in advance and ensure that the cell confluence is 80% on the next day, and the time should not exceed 24 hours;
[0124] ② Prepare transfection system B: 80 μL PEI + Opti medium to 750 μL, let stand at RT for 5 minutes;
[0125] ③ Prepare transfection system A: pAAV 2: 3.5μg, helper: 10μg, target plasmid 3.5μg + opti medium to 750μL;
[0126] ④Mix liquid A / B, let stand at RT for 20 min, transfer liquid B to liquid A, add slowly, and mix gently by pipetting;
[0127] ⑤ Add transfection reagent A / B solution to the cell culture medium, culture at 37°C, change the medium after 6 hours, and collect the cell culture medium supernatant 48 hours and 72 hours after the medium change;
[0128] ⑥ Filter the culture medium supernatant with a 0.45 μm filter;
[0129] ⑦ Add 20% PEG8000 solvent according to the virus volume;
[0130] ⑧ Place at 4°C overnight;
[0131] ⑨ The next day, centrifuge at 8000rpm for 1h, take out the pellet immediately after centrifugation, mark it, discard the supernatant, resuspend it with 200μL DPBS, mix it well and transfer it to a 1.5mL tube, take some samples for titer detection, and store the rest in a -80℃ refrigerator after marking the time and date.
[0132] (2) Adeno-associated virus infection of cells and observation
[0133] ①Transfect HEK293T, HeLa, HepG2 and NSC34 cells into six-well plates. The cell density on the second day was 5×10 4 The virus suspension was added to the cell culture medium at a ratio of 50,000 adeno-associated viruses per cell, and the cells were returned to the 37°C incubator for culture.
[0134] ② After 48 hours of exposure, observe the green fluorescence under a fluorescence microscope.
[0135] 2. Experimental results
[0136] The results showed that the HBVpS, HBVpL, HBVpM, hALBpS, hALBpL, FGBp, and SERPINA promoters all showed a certain liver-specific expression activity. Among them, the HBVpS, HBVpL, and HBVpM promoters had high expression activity, and the hALBpS, hALBpL, FGBp, and SERPINA promoters had high expression specificity in HepG2 (see Figure 8 A-8H).
[0137] Example 4 Comparison of specific activation effects of different promoters in in vitro cells
[0138] 1. Adeno-associated virus packaging
[0139] (1) Plate HEK293T cells into the corresponding culture dish in advance and ensure that the cell confluence is 80% on the next day, and the time should not exceed 24 hours;
[0140] (2) Prepare transfection system B: 80 μL PEI + Opti medium to 750 μL, let stand at RT for 5 min;
[0141] (3) Prepare transfection system A: pAAV2: 3.5 μg, helper: 10 μg, target plasmid 3.5 μg + opti medium to 750 μL;
[0142] (4) Mix solution A and solution B, let stand at RT for 20 min, transfer solution B to solution A, add slowly, and mix by gently pipetting;
[0143] (5) Add transfection reagent A / B solution to the cell culture medium, culture at 37°C, change the medium after 6 hours, and collect the cell culture medium supernatant 48 hours and 72 hours after the medium change;
[0144] (6) Filter the culture supernatant with a 0.45 μm filter;
[0145] (7) Add 20% PEG8000 solvent according to the virus volume;
[0146] (8) Place at 4°C overnight;
[0147] (9) The next day, centrifuge at 8000 rpm for 1 h. Remove the pellet immediately after centrifugation, mark the precipitate, discard the supernatant, resuspend with 200 μL DPBS, mix well and transfer to a 1.5 mL tube. Take a portion of the sample for titer detection and store the rest in a -80°C refrigerator after marking the time and date.
[0148] 2. Cell culture
[0149] Cell recovery: Take out the frozen cells from the liquid nitrogen tank, thaw quickly in a 37℃ water bath, add 1mL DMEM complete medium to the cryopreservation tube to resuspend, centrifuge at 1000r / min for 5min, discard the supernatant, resuspend with DMEM complete medium and plate in a 100mm cell culture dish at 37℃, 5% CO 2 Culture in an incubator.
[0150] Cell plating: Digest with TrypLE: DPBS = 1:1 working solution, add 2 mL of TrypLE working solution to each 100 mm cell culture dish, place at 37 ° C for 3 min, terminate digestion with 4 mL of DMEM complete medium, pour the cell suspension into a 15 mL centrifuge tube, centrifuge at 1000 r / min for 5 min, discard the supernatant, resuspend with 10 mL of culture medium, and plate in three 6-well cell culture plates at 37 ° C, 5% CO 2 Culture in an incubator.
[0151] 3. Adeno-associated virus infection of cells
[0152] HEK293T, HeLa, HepG2 and NSC34 cells were transferred into six-well plates. The cell density was 5×10 4The virus suspension was added to the cell culture medium at a ratio of 50,000 adeno-associated viruses per cell, and the cells were returned to the 37°C incubator for 48 h.
[0153] 4. RNA Extraction
[0154] (1) Resuspend the cells in each well with 1 mL of Trizol reagent, collect them into a 1.5 mL RNase-free EP tube, add 0.2 mL of chloroform, shake vigorously for 15 seconds, and let stand for 2 minutes;
[0155] (2) Centrifuge at 4°C, 12,000 rpm for 15 min and collect the supernatant (be careful not to collect the intermediate protein layer);
[0156] (3) Add 0.5 mL of isopropanol, gently mix the liquid in the tube, and let it stand at room temperature for 10 min;
[0157] (4) Centrifuge at 4°C, 12,000 rpm for 10 min and discard the supernatant;
[0158] (5) Add 1 mL of 75% ethanol (prepared with DEPC water) and gently wash the precipitate;
[0159] (6) Centrifuge at 4°C, 7500 rpm for 5 min and discard the supernatant;
[0160] (7) The precipitate is naturally dried and then dissolved by adding appropriate amount of DEPC water;
[0161] (8) Take a small amount to test the RNA purity (OD260 / 280) and integrity, record the RNA concentration, and store at 80°C for future use.
[0162] 5. Reverse transcription
[0163] Take RNA of corresponding mass into a 100 μL EP tube, add gDNA Remover, Oligo(dT), Primer, RMIX, EMIX and RNase-free water, incubate at 42°C for 15 min to synthesize the first-strand cDNA and remove the residual genomic DNA in the RNA template; heat at 85°C for 5 s to inactivate TransScript RT / RI and gDNA Remover.
[0164] 6. Fluorescence quantitative PCR
[0165] The components used in fluorescent quantitative PCR and the amounts of each component are shown in Table 3 below.
[0166] Table 3 Components and dosages used in fluorescence quantitative PCR
[0167]
[0168] The EGFP primer sequences are as follows:
[0169] Forward: 5'-CGTAACGGCCACAAGTTCA-3'(SEQ ID NO:12)
[0170] Reverse: 5'-CTTCATGTGGTCGGGGTAGC-3'(SEQ ID NO:13)
[0171] 7. Experimental results
[0172] The results showed that the HBVpS, HBVpL, HBVpM, hALBpS, hALBpL, FGBp, and SERPINA promoters all exhibited certain liver-specific expression activity in cells in vitro, among which the HBVpS, HBVpL, and HBVpM promoters were highly active in HepG2 cells (see Fig. 9 A and 9B), hALBpS, hALBpL, FGBp, and SERPINA are highly specific in HepG2 cells (see Fig. 9 A and 9C).
[0173] Example 5 Levels of F9 expression in vivo by liver-specific promoter
[0174] 1. Experimental methods
[0175] In this experiment, AAV2 / 8 was used to package the liver-specific promoter-F9 gene, and the AAV was used to inject C57BL6 mice into the tail vein, and mouse tissues were collected at different time points to detect the expression of F9 mRNA in different tissues. Among them, the amino acid sequence of F9 is shown in SEQ ID NO:8, the nucleotide sequence of F9 is shown in SEQ ID NO:9, the amino acid sequence of F9 / 384L is shown in SEQ ID NO:10, and the nucleotide sequence of F9 / 384L is shown in SEQ ID NO:11.
[0176] The specific experimental methods are as follows:
[0177] (1) Fix the mouse with a mouse fixator, which has a vent at the front to ensure the mouse's breathing and a rear to pull out the tail so that the tail is completely exposed;
[0178] (2) Wipe the mouse’s tail with alcohol to dilate the blood vessels;
[0179] (3) Use a syringe to draw up the solution, hold the syringe at a 30-degree angle for venous puncture, and push the solution without resistance. There are three tail veins in the mouse's tail, one on the back and one on each side. Since the back vein is deeper and thinner, the two on the side are generally selected. Each mouse is injected with 200 μL of adeno-associated virus with a total titer of 1011. Three mice per group.
[0180] (4) On the 7th and 21st days after injection, the liver, kidney, heart, brain, testis, quadriceps, large intestine, small intestine, stomach, and lung tissues of the mice were collected to extract mRNA. After reverse transcription, qPCR was used to detect the F9 mRNA content in different organs.
[0181] The specific qPCR detection method is as described in Example 4, and the F9 primer sequence is as follows:
[0182] Forward: 5'-GCGGCAGTTGCAAGGATG-3'(SEQ ID NO:14)
[0183] Reverse: 5'-CCTCAGTACAGGAGCAAACCA-3'(SEQ ID NO:15)
[0184] 2. Experimental results
[0185] The results showed that the two liver-specific promoters, HBVpS and hALBpL, could activate the specific expression of F9 and F9 / 384L in the mouse liver, with almost no expression in other organs (see Fig.10 A-10C).
[0186] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. A group of recombinant liver-specific promoters, characterized in that The recombinant liver-specific promoter includes HBVpS promoter, HBVpL promoter or HBVpM promoter; The nucleotide sequence of the HBVpS promoter is shown in SEQ ID NO:6; The nucleotide sequence of the HBVpL promoter is shown in SEQ ID NO:4; The nucleotide sequence of the HBVpM promoter is shown in SEQ ID NO:
5.
2. A group of recombinant nucleic acid molecules, characterized in that: The recombinant nucleic acid molecule comprises the recombinant liver-specific promoter according to claim 1; The nucleotide sequence of the recombinant nucleic acid molecule is shown in any one of SEQ ID NO:6, SEQ ID NO:4, and SEQ ID NO:
5.
3. A set of expression cassettes, characterized in that, The expression cassette comprises the recombinant nucleic acid molecule of claim 2 and a nucleotide sequence encoding a target gene.
4. The expression cassette according to claim 3, characterized in that The recombinant nucleic acid molecule of claim 2 can be operably linked to the upstream of the target gene.
5. The expression cassette according to claim 4, characterized in that The recombinant nucleic acid molecule can promote the specific expression of the target gene in liver tissue.
6. The expression cassette according to claim 5, characterized in that The target genes include coagulation factor IX (F9), F9 mutant (F9 / 384L), coagulation factor VIII (F8), coagulation factor XI (F11), growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiogenin, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factor I (IGF-I), acid α-glucosidase (GAA), insulin growth factor II (IGF-II), and / or fluorescent protein genes.
7. The expression cassette according to claim 6, characterized in that The fluorescent proteins include EGFP, mCherry, GFP, YFP, EYFP, BFP, EBFP, CFP, ECFP, RFP, hfGFP, hfYFP, OFP, dsRed, qFP611, Dronpa, TagRFP, KFP, EosFP, IrisFP, Dendra, Kaede, and / or KikGr1.
8. A group of recombinant expression vectors, characterized in that: The recombinant expression vector comprises the recombinant nucleic acid molecule of claim 2 or the expression cassette of any one of claims 3-7.
9. The recombinant expression vector according to claim 8, characterized in that The expression vector includes a viral vector and a plasmid vector.
10. The recombinant expression vector according to claim 9, characterized in that: The viral vectors include adeno-associated viral vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, alphaviral vectors, herpes virus vectors, Epstein-Barr virus vectors, and vaccinia virus vectors.
11. The recombinant expression vector according to claim 10, characterized in that: The adeno-associated virus vectors include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 8, and AAV2 / 9.
12. A mammalian host cell, characterized in that The mammalian host cell comprises the expression cassette of any one of claims 3-7 or the recombinant expression vector of any one of claims 8-11.
13. The mammalian host cell according to claim 12, characterized in that The mammalian host cell is obtained by introducing the expression cassette according to any one of claims 3 to 7 or the recombinant expression vector according to any one of claims 8 to 11 into a host cell.
14. The mammalian host cell according to claim 13, characterized in that The introduction method includes lipid transfection, microinjection, electroporation, plasmid vector, retroviral vector, lentiviral vector, poxvirus vector, herpes simplex virus vector, adenovirus vector, and adeno-associated virus vector.
15. The mammalian host cell according to claim 14, characterized in that The host cells include mouse cells, rat cells, hamster cells, monkey cells, and / or human cells.
16. A pharmaceutical composition for treating liver-related diseases, characterized in that: The pharmaceutical composition comprises the expression cassette of any one of claims 3-7, the recombinant expression vector of any one of claims 8-11, or the mammalian host cell of any one of claims 12-15.
17. The pharmaceutical composition according to claim 16, characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.
18. The pharmaceutical composition according to claim 16, characterized in that The target gene in the expression cassette includes coagulation factor IX (F9), F9 mutant (F9 / 384L), coagulation factor VIII (F8), coagulation factor XI (F11), growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiogenin, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factor I (IGF-I), acid α-glucosidase (GAA), and / or insulin growth factor II (IGF-II).
19. The pharmaceutical composition according to claim 16, characterized in that The liver-related diseases include hemophilia, hepatitis, liver fibrosis, cirrhosis, alcoholic liver disease, fatty liver disease, liver cancer, diabetes, obesity, hyperlipidemia, hereditary cholestasis, Wilson's disease, hereditary hemochromatosis, type 1 tyrosinemia, alpha-1 antitrypsin deficiency, argininosuccinic aciduria, and / or Pompe's disease.
20. The pharmaceutical composition according to claim 19, characterized in that The hemophilia includes hemophilia A, hemophilia B, and / or hemophilia C.
21. The pharmaceutical composition according to claim 20, characterized in that The hemophilia is hemophilia B.
22. A liver-specific tracer, characterized in that: The liver-specific tracer comprises the expression cassette of any one of claims 3 to 7 or the recombinant expression vector of any one of claims 8 to 11.
23. The liver-specific tracer according to claim 22, characterized in that The target gene in the expression cassette includes a fluorescent protein gene.
24. The liver-specific tracer according to claim 23, characterized in that The fluorescent proteins include EGFP, mCherry, GFP, YFP, EYFP, BFP, EBFP, CFP, ECFP, RFP, hfGFP, hfYFP, OFP, dsRed, qFP611, Dronpa, TagRFP, KFP, EosFP, IrisFP, Dendra, Kaede, and / or KikGr1.
25. Use of the recombinant liver-specific promoter according to claim 1, the recombinant nucleic acid molecule according to claim 2, the expression cassette according to any one of claims 3 to 7, or the recombinant expression vector according to any one of claims 8 to 11 in promoting the specific expression of a target gene or nucleic acid fragment in liver tissue.
26. Use of the recombinant liver-specific promoter of claim 1, the recombinant nucleic acid molecule of claim 2, the expression cassette of any one of claims 3-7, the recombinant expression vector of any one of claims 8-11 or the mammalian host cell of any one of claims 12-15 in the preparation of a drug for treating liver-related diseases.
27. The use according to claim 26, characterized in that The liver-related diseases include hemophilia, hepatitis, liver fibrosis, cirrhosis, alcoholic liver disease, fatty liver disease, liver cancer, diabetes, obesity, hyperlipidemia, hereditary cholestasis, Wilson's disease, hereditary hemochromatosis, type 1 tyrosinemia, alpha-1 antitrypsin deficiency, argininosuccinic aciduria, and / or Pompe's disease.
28. The use according to claim 27, characterized in that The hemophilia includes hemophilia A, hemophilia B, and / or hemophilia C.
29. The use according to claim 28, characterized in that The hemophilia is hemophilia B.
Citation Information
Cited By
Product, system and method of cell cultivation
US12668774B2
Culture media based on protein hydrolysate and a process for preparing thereof
US12686847B2
Pet food, methods and devices for producing pet food
US12772996B2
